miR-206 then exerts its anti-tumorigenic effects by targeting and suppressing the Met receptor tyrosine kinase (c-Met), which is overexpressed in both ARMS and ERMS [125], and has been implicated in RMS pathogenesis [54,55]. Here, MET is linked to embryonal rhabdomyosarcoma.